Loading clinical trials...
Loading clinical trials...
Iparomlimab and Tuvonralimab Injection (QL1706) Combined With Bevacizumab for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma (HCC) With High Risk of Recurrence: A Multicenter, Open-Label, Single-Arm, Phase II Study
Conditions
Interventions
Iparomlimab and Tuvonralimab Injection (QL1706) plus bevacizumab
Start Date
May 1, 2025
Primary Completion Date
October 1, 2026
Completion Date
December 31, 2027
Last Updated
May 6, 2025
NCT06764355
NCT07285850
NCT06576973
NCT07106827
NCT06999837
NCT05760612
Lead Sponsor
The Affiliated Hospital of Xuzhou Medical University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions